Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by NuRx Pharmaceuticals, Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
NuRx Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00964132
First received: August 20, 2009
Last updated: September 2, 2009
Last verified: September 2009
  Purpose

The purpose of this study is to determine whether NRX 194204 is effective in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC).


Condition Intervention Phase
Non-small Cell Lung Cancer
Drug: NRX194204
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multiple-Center, Open-Label, Study of the Safety and Efficacy of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:


Further study details as provided by NuRx Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Overall objective tumor response rate [ Time Frame: 7 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression free survival [ Time Frame: 7 months ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 7 months ] [ Designated as safety issue: No ]
  • Overall safety and toxicity of NRX 194204 in NSCLC patients [ Time Frame: 7 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 48
Study Start Date: March 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NRX194204 Drug: NRX194204
Once Daily, Oral

Detailed Description:

Numerous studies in pre-clinical models and in human clinical trials have clearly established the potential for the use of rexinoids in the treatment and prevention of cancer. NRX 194204, a second generation rexinoid, is a highly potent and specific activator of RXRs. Because NRX 194204 is significantly more selective for the RXRs relative to the RARs than a first generation approved drug, it is associated with fewer adverse events in clinical use. This study seeks to investigate NRX 194204 monotherapy in patients who have failed any 2 prior therapies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, age ≥ 18 years
  • Histologically confirmed advanced stage III or IV NSCLC that is recurrent or has progressed after treatment. Failure on at least 2 NSCLC treatment regimens
  • Uni-dimensionally measurable NSCLC defined as at least one lesion that can be measured in at least one dimension (longest diameter to be recorded) as ≥ 2cm with conventional techniques or as ≥ 1cm on spiral CT scan.
  • Patients are eligible if disease free from previous malignancies, other than a previous NSCLC, for greater than two years. Patients with a history of prior basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix are not excluded.
  • Karnofsky performance status ≥ 60 (Attachment 14.4) or ECOG performance status 0-2
  • Life expectancy > 12 weeks.
  • Able to swallow capsule form of the drug.
  • Hematology:

    • Hemoglobin > 8.5 g/dl;
    • Platelets > 100,000 cells/mm3;
    • Neutrophils > 1500 cells/mm3;
    • PT and PTT within normal limits, except for patients receiving Coumadin for thromboembolic prophylaxis only, in whom INR of less than 2 will be allowable.
  • Biochemistry:

    • Total bilirubin < 1.5 x ULN;
    • AST/ALT < 3.0 x ULN;
    • Serum creatinine < 2.0 mg/dl;
    • Serum calcium < 11.5 mg/dl;
    • Fasting serum triglycerides < 2.5 x ULN.
  • Negative urine pregnancy test for women of child-bearing potential at screening and on Day 1, and agreement by both women and men of reproductive potential to use two reliable forms of contraception during therapy and for 1 month following discontinuation of therapy unless abstinence is the chosen birth control method.
  • Able to follow study instructions, accessible for treatment and follow-up, and likely to complete all study requirements.

Exclusion Criteria:

  • Significant medical history or unstable medical condition (congestive heart failure, recent myocardial infarction within 3 months, unstable angina, active systemic infection, uncontrolled hypertension). Patients with controlled diabetes will be allowed.
  • Prior treatment with bexarotene (Targretin) or NRX 194204.
  • Current enrollment in an investigational drug or device study or participation in such a study within 21 days of entry into this study.
  • Known sensitivity to any of the ingredients in the study medication.
  • Known HIV-positive patients.
  • Females who are pregnant, nursing, or planning a pregnancy.
  • Major surgery within previous 4 weeks; large field radiation therapy (> 25% of the patient's total marrow) or chemotherapy (including investigational agents or participation in another clinical study) within previous 3 weeks; mitomycin C or nitrosoureas within 6 weeks. In all instances, patients must have fully recovered from acute toxicities related to prior therapies.
  • Systemic retinoid therapy, or Vitamin A at dosages > 15,000 IU per day, during previous 4 weeks.
  • Patients with a history of pancreatitis or at significant risk of developing pancreatitis (e.g., uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity).
  • Primary brain tumors, active brain metastasis including progression from last scan or evidence of cerebral edema, or clinical symptoms of brain metastasis.
  • Condition or situation which, in the investigator's opinion, may put patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00964132

Locations
United States, California
Dr. Pandit
Fountain Valley, California, United States, 92708
UCSD Moores Cancer Center
La Jolla,, California, United States, 92093-0698
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
United States, New Hampshire
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Somerset Oncology Hematology Associates
Somerville, New Jersey, United States, 08876
United States, Washington
Swedish Cancer Institute
Seattle,, Washington, United States, 98104
Sponsors and Collaborators
NuRx Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Roshantha A. Chandraratna, PhD, MBA, Chief Scientific Officer, NuRx Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00964132     History of Changes
Other Study ID Numbers: 194204-203
Study First Received: August 20, 2009
Last Updated: September 2, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by NuRx Pharmaceuticals, Inc.:
Non-Small Cell Lung Cancer
NSCLC
Rexinoid
NRX194204
Lung Cancer
RXR

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 21, 2014